IP Library Granted Patent US 12,275,950
Granted Patent B2
US 12,275,950 · App. 16/099,134 · Granted Apr 15, 2025

In vitro method of reprogramming fibroblast cells into induced pluripotent stem cells by transcription factors mRNAs co-transfected with SOCS1 mRNA wherein the mRNAs have a poly-A tail of at least 2000 adenines

Inventors: Marion Jurk (Pulheim, DE); Stefan Wild (Cologne, DE); Andreas Bosio (Cologne, DE)
Assignee: MILTENYI BIOTEC B.V. & CO. KG
C12N15/87C07K14/4703C12N5/0636C12N5/0662C12N5/0696C12N5/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,275,950
App. No.
16/099,134
Granted
Apr 15, 2025
Kind
B2
Abstract

The present invention provides the use of a nucleic acid encoding SOCS1 for enhancing the efficacy of introducing at least one nucleic acid of interest into a cell; a method of repeated transfection of a cell with at least one nucleic acid of interest comprising the steps of adding a) nucleic acid encoding SOCS1, and simultaneously or subsequently b) at least one nucleic acid of interest encoding at least one polypeptide of interest, wherein at least step b) is repeated at least once; and a method of electroporation of a cell with at least one nucleic acid of interest comprising the steps of adding to the cell a) a nucleic acid encoding SOCS1, and simultaneously or subsequently b) said at least one nucleic of interest. The at least one nucleic acid of interest and the nucleic acid encoding SOCS1 may be mRNAs, wherein each of said mRNAs has a poly(A) tail at its 3′ end comprising at least 200 adenines.

Claims (5)

1. An in vitro method of repeated transfection of a fibroblast cell with at least one mRNA encoding a reprogramming factor, comprising introducing to the fibroblast cell: a) Suppressor Of Cytokine Signaling 1 (SOCS1) mRNA; and simultaneously or subsequently b) the at least one mRNA encoding a reprogramming factor; wherein the step b) is repeated at least once, and wherein the SOCS1 mRNA and the at least one mRNA encoding the reprogramming factor have a poly (A) tail at its 3′ end comprising at least 2000 adenines, respectively, wherein the reprogramming factor induces reprograming of the fibroblast cell into an induced pluripotent stem cell (iPSC), wherein the at least one mRNA encoding the reprogramming factor is an mRNA reprogramming mixture comprising mRNAs encoding for Oct3/4, Sox2, Klf4, Lin28, c-Myc, and Nanog.

2. The method according to claim 1 , wherein the step b) is repeated at least three times.

3. The method according to claim 2 , wherein the step b) is repeated within 4 hours to 48 hours between a first time and a second time.

4. The method according to claim 1 , wherein the method results in an increased expression of the mRNA encoding the reprogramming factor compared to a corresponding method wherein the SOCS1 mRNA is not co-introduced.

5. The method according to claim 4 , wherein the method results in an increased reprogramming efficiency of the fibroblast cell compared to a corresponding method wherein the SOCS1 mRNA is not co-introduced.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2019
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 051443/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2019
From: JURK, MARION; WILD, STEFAN; BOSIO, ANDREAS
To: MILTENYI BIOTEC GMBH
Reel/Frame 048674/0181 →